Among others, the US Food and Drug Administration (FDA) has approved several CD19-directed CAR T cell therapeutic products for the treatment of hematological malignancies, such as types of B cell lymphomas and acute lymphoblastic leukemia (ALL) [7]. Here, CD19 is linked to acute lymphoblastic leukemia.